Details About Generic Salt ::  Albutero

Main Medicine Class:: Bronchodilator, Sympathomimetic   

(al-BYOO-ter-ahl)

Airet

Solution for inhalation: 0.083% (as sulfate)

Proventil

Tablets: 2 mg (as sulfate), 4 mg (as sulfate)

Syrup: 2 mg (as sulfate) per 5 mL

Aerosol: Each actuation delivers 90 mcg albuterol

Solution for inhalation: 0.083% (as sulfate), 0.5% (as sulfate)

Proventil HFA

Aerosol: Each actuation delivers 90 mcg albuterol (as sulfate)

Proventil Repetabs

Tablets, extended-release: 4 mg (as sulfate)

Ventolin

Tablets: 2 mg (as sulfate), 4 mg (as sulfate)

Syrup: 2 mg (as sulfate) per 5 mL

Aerosol: Each actuation delivers 90 mcg albuterol

Solution for inhalation: 0.5% (as sulfate)

Ventolin Nebules

Solution for inhalation: 0.083% (as sulfate)

Ventolin Rotacaps

Capsules for inhalation: 200 mcg microfine (as sulate)

Volmax

Tablets, extended-release: 4 mg (as sulfate), 8 mg (as sulfate)

Alti-Salbutamol Sulfate

Asmavent

Gen-Salbutamol Sterinebs P.F.

Novo-Salmol

PMS-Salbutamol Respirator Solution

Rho-Salbutamol

Salbutamol Nebuamp

Ventodisk Disk/Diskhaler

Ventolin Injection

Ventolin Nebules P.F./Respirator Solution

Ventolin Rotocaps/Rotahaler

Ventolin Tablets

Class: Bronchodilator, Sympathomimetic

 Indications Prevention and treatment of reversible bronchospasm associated with asthma and other obstructive pulmonary diseases.

Adjunctive treatment of hyperkalemia in patients undergoing dialysis.

 Contraindications Cardiac tachyarrhythmias.

 Route/Dosage

Inhalation Aerosol

ADULTS AND CHILDREN ³ 4 yr (³ 12 yr for Proventil): 1 to 2 inhalations q 4 to 6 hr. prevention of exercise-induced bronchospasm: 2 inhalations 15 min before exercise.

Inhalation Solution

ADULTS AND CHILDREN ³ 2 yr: 2.5 mg/dose 3 to 4 times/day by nebulization. CHILDREN 2 to 12 yr (AccuNeb): 1.25 mg or 0.63 mg 3 to 4 times/day by nebulization.

Oral

ADULTS AND CHILDREN ³ 12 yr: PO 2 to 4 mg/dose 3 to 4 times/day. Do not exceed 32 mg/day. CHILDREN 6 to 12 yr: PO 2 mg/dose 3 to 4 times/day. Do not exceed 24 mg/day. CHILDREN 2 to 6 yr: PO 0.1 to 0.2 mg/kg/dose 3 times/day. Do not exceed 12 mg/day. ADULTS AND CHILDREN > 12 yr, Extended-Release (Volmax): PO 8 mg q 12 hr. 4 mg q 12 hr may be sufficient in some patients. May be cautiously increased stepwise under physician supervision to a max of 16 mg bid (max 32 mg/day). ADULTS AND CHILDREN > 12 yr, Extended-Release (Proventil Repetabs): PO 4 to 8 mg q 12 hr. May be cautiously increased stepwise to a max of 16 mg bid (max 32 mg/day). CHILDREN 6 to 12 yr, Extended-Release (Volmax): PO 4 mg q 12 hr. May be cautiously increased by steps under health care provider supervision to a max of 24 mg/day in divided doses if symptoms are not controlled. CHILDREN 6 to 12 yr, Extended-Release (Proventil Repetabs): PO 4 q 12 hr. May be cautiously increased stepwise to a max of 12 mg bid.

Syrup

ADULTS AND CHILDREN > 12 yr: 2 or 4 mg (1 to 2 tsp) 3 or 4 times/day. Doses of > 4 mg 4 times/day may be appropriate when patient fails to respond. CHILDREN 6 to 12 yr: 2 mg (1 tsp) 3 or 4 times/day. Doses of 2 mg 4 times/day may be cautiously increased. Do not exceed 24 mg/day in divided doses. CHILDREN 2 to 6 yr: Initiate at 0.1 mg/kg 3 times/day. Dose may be increased 2 mg 3 times/day. Do not exceed 2 mg 3 times/day. Dose may be increased to 0.2 mg/kg 3 times/day, but not to exceed 4 mg 3 times/day. Elderly and those sensitive to b-adrenergic stimulation: Restrict initial dose to 2 mg (1 tsp) 3 or 4 times/day. Individualize dosage thereafter.

 Interactions

Beta-Blockers: Severe bronchospasms may be produced in asthmatic patients taking albuterol. Digoxin: Albuterol may decrease serum digoxin levels. Diuretics: ECG changes and hypokalemia associated with these diuretics may worsen with albuterol coadministration.

 Lab Test Interferences None well documented.

 Adverse Reactions

CARDIOVASCULAR: Palpitations; tachycardia; elevated BP; chest tightness; angina. CNS: Tremor; dizziness; hyperactivity; nervousness; headache; insomnia; weakness; drowsiness; restlessness. EENT: Dry mouth; throat irritation. GI: Nausea; vomiting; heartburn; diarrhea. GU: Urinary retention. RESPIRATORY: Cough; bronchospasm; wheezing; dyspnea. OTHER: Flushing; sweating; anorexia; unusual sensory changes.

 Precautions

Pregnancy: Category C. Lactation: Unknown. Labor and Delivery: May inhibit uterine contractions. CHILDREN: Albuterol aerosol and inhalation powder in children < 4 yr and albuterol solution for inhalation in children < 2 yr have not been established. Cardiovascular Effects: Toxic symptoms may occur in patients with cardiovascular disorders. CNS Effects: CNS stimulation may occur; use cautiously in patients with history of seizures or hyperthyroidism. Diabetes: Dosage adjustment of insulin or oral hypoglycemic agent may be required. Excessive Use: Paradoxical bronchospasm and cardiac arrest have been associated with excessive inhalant use. Hypokalemia: Decreases in potassium levels have occurred. Tolerance: If previously effective dose fails to provide relief, therapy may need to be reassessed.

PATIENT CARE CONSIDERATIONS

 Administration/Storage

• Do not crush or chew tablets.
• Administer oral preparations with meals to minimize GI upset.
• Use before other inhalation therapy and before postural drainage.
• Allow 1 to 2 min between metered-dose inhalations and 5 min before administering other inhalant medications. Permit patient to rinse mouth after each completed inhalation dose.
• Store at room temperature. Refrigeration of syrup improves palatability.

 Assessment/Interventions

• Obtain patient history, including drug history and any known allergies.
• Check pulse, BP, respiration, and lung sounds before and after administration.
• Review baseline and any follow-up ECG. If patient takes digoxin, check baseline and any follow-up serum digoxin levels.
• If patient is diabetic, check baseline and follow-up blood sugar levels.
• If bronchospasm occurs, withhold drug and report to health care provider.
• During pregnancy, monitor fetal heart rate and report tachycardia (> 140 bpm).

OVERDOSAGE: SIGNS & SYMPTOMS   Tremor, palpitations, tachycardia, elevated BP, seizures

 Patient/Family Education

• Tell patient not to chew or crush capsules.
• Teach patient correct method for using metered-dose inhaler. Have patient demonstrate proper technique, including timing between inhalations.
• Instruct patient in home monitoring of pulse and BP.
• Advise patient to maintain fluid intake of 2000 mL/day and to rinse mouth after each complete dose.
• Instruct patient not to use otc inhalers without consulting health care provider.
• Instruct patient to contact health care provider if symptoms are not relieved by normal dose.
• Tell patient to report adverse reactions or side effects.

–>

Drugs Class ::

Indications for Drugs ::

 Indications Prevention and treatment of reversible bronchospasm associated with asthma and other obstructive pulmonary diseases.

Adjunctive treatment of hyperkalemia in patients undergoing dialysis.

Drug Dose ::

 Route/Dosage

Inhalation Aerosol

ADULTS AND CHILDREN ³ 4 yr (³ 12 yr for Proventil): 1 to 2 inhalations q 4 to 6 hr. prevention of exercise-induced bronchospasm: 2 inhalations 15 min before exercise.

Inhalation Solution

ADULTS AND CHILDREN ³ 2 yr: 2.5 mg/dose 3 to 4 times/day by nebulization. CHILDREN 2 to 12 yr (AccuNeb): 1.25 mg or 0.63 mg 3 to 4 times/day by nebulization.

Oral

ADULTS AND CHILDREN ³ 12 yr: PO 2 to 4 mg/dose 3 to 4 times/day. Do not exceed 32 mg/day. CHILDREN 6 to 12 yr: PO 2 mg/dose 3 to 4 times/day. Do not exceed 24 mg/day. CHILDREN 2 to 6 yr: PO 0.1 to 0.2 mg/kg/dose 3 times/day. Do not exceed 12 mg/day. ADULTS AND CHILDREN > 12 yr, Extended-Release (Volmax): PO 8 mg q 12 hr. 4 mg q 12 hr may be sufficient in some patients. May be cautiously increased stepwise under physician supervision to a max of 16 mg bid (max 32 mg/day). ADULTS AND CHILDREN > 12 yr, Extended-Release (Proventil Repetabs): PO 4 to 8 mg q 12 hr. May be cautiously increased stepwise to a max of 16 mg bid (max 32 mg/day). CHILDREN 6 to 12 yr, Extended-Release (Volmax): PO 4 mg q 12 hr. May be cautiously increased by steps under health care provider supervision to a max of 24 mg/day in divided doses if symptoms are not controlled. CHILDREN 6 to 12 yr, Extended-Release (Proventil Repetabs): PO 4 q 12 hr. May be cautiously increased stepwise to a max of 12 mg bid.

Syrup

ADULTS AND CHILDREN > 12 yr: 2 or 4 mg (1 to 2 tsp) 3 or 4 times/day. Doses of > 4 mg 4 times/day may be appropriate when patient fails to respond. CHILDREN 6 to 12 yr: 2 mg (1 tsp) 3 or 4 times/day. Doses of 2 mg 4 times/day may be cautiously increased. Do not exceed 24 mg/day in divided doses. CHILDREN 2 to 6 yr: Initiate at 0.1 mg/kg 3 times/day. Dose may be increased 2 mg 3 times/day. Do not exceed 2 mg 3 times/day. Dose may be increased to 0.2 mg/kg 3 times/day, but not to exceed 4 mg 3 times/day. Elderly and those sensitive to b-adrenergic stimulation: Restrict initial dose to 2 mg (1 tsp) 3 or 4 times/day. Individualize dosage thereafter.

Contraindication ::

 Contraindications Cardiac tachyarrhythmias.

Drug Precautions ::

 Precautions

Pregnancy: Category C. Lactation: Unknown. Labor and Delivery: May inhibit uterine contractions. CHILDREN: Albuterol aerosol and inhalation powder in children < 4 yr and albuterol solution for inhalation in children < 2 yr have not been established. Cardiovascular Effects: Toxic symptoms may occur in patients with cardiovascular disorders. CNS Effects: CNS stimulation may occur; use cautiously in patients with history of seizures or hyperthyroidism. Diabetes: Dosage adjustment of insulin or oral hypoglycemic agent may be required. Excessive Use: Paradoxical bronchospasm and cardiac arrest have been associated with excessive inhalant use. Hypokalemia: Decreases in potassium levels have occurred. Tolerance: If previously effective dose fails to provide relief, therapy may need to be reassessed.

Drug Side Effects ::

 Adverse Reactions

CARDIOVASCULAR: Palpitations; tachycardia; elevated BP; chest tightness; angina. CNS: Tremor; dizziness; hyperactivity; nervousness; headache; insomnia; weakness; drowsiness; restlessness. EENT: Dry mouth; throat irritation. GI: Nausea; vomiting; heartburn; diarrhea. GU: Urinary retention. RESPIRATORY: Cough; bronchospasm; wheezing; dyspnea. OTHER: Flushing; sweating; anorexia; unusual sensory changes.

Drug Mode of Action ::  

Drug Interactions ::

 Interactions

Beta-Blockers: Severe bronchospasms may be produced in asthmatic patients taking albuterol. Digoxin: Albuterol may decrease serum digoxin levels. Diuretics: ECG changes and hypokalemia associated with these diuretics may worsen with albuterol coadministration.

Drug Assesment ::

 Assessment/Interventions

• Obtain patient history, including drug history and any known allergies.
• Check pulse, BP, respiration, and lung sounds before and after administration.
• Review baseline and any follow-up ECG. If patient takes digoxin, check baseline and any follow-up serum digoxin levels.
• If patient is diabetic, check baseline and follow-up blood sugar levels.
• If bronchospasm occurs, withhold drug and report to health care provider.
• During pregnancy, monitor fetal heart rate and report tachycardia (> 140 bpm).

Drug Storage/Management ::

 Administration/Storage

• Do not crush or chew tablets.
• Administer oral preparations with meals to minimize GI upset.
• Use before other inhalation therapy and before postural drainage.
• Allow 1 to 2 min between metered-dose inhalations and 5 min before administering other inhalant medications. Permit patient to rinse mouth after each completed inhalation dose.
• Store at room temperature. Refrigeration of syrup improves palatability.

Drug Notes ::

 Patient/Family Education

• Tell patient not to chew or crush capsules.
• Teach patient correct method for using metered-dose inhaler. Have patient demonstrate proper technique, including timing between inhalations.
• Instruct patient in home monitoring of pulse and BP.
• Advise patient to maintain fluid intake of 2000 mL/day and to rinse mouth after each complete dose.
• Instruct patient not to use otc inhalers without consulting health care provider.
• Instruct patient to contact health care provider if symptoms are not relieved by normal dose.
• Tell patient to report adverse reactions or side effects.

–>

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.